Loading
HKSEHealthcareMedical - Diagnostics & Research
Latest quote
HK$22.64
+HK$0.16 · +0.71%
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into three primary divisions: Non-Clinical Studies, Clinical Trial and Related Services, and Research Model Sales. The Non-Clinical Studies segment specializes in comprehensive drug safety assessments, pharmacokinetic and drug metabolism research, and pharmacology and efficacy investigations. Within its Clinical Trial and Related Services segment, the firm delivers clinical contract research organization (CRO) support, co-manages specialized Phase I clinical research facilities, and provides bioanalytical testing. The Research Model Sales division is responsible for the development, breeding, and distribution of diverse animal models for research purposes, encompassing non-human primates and rodents. Furthermore, Joinn Laboratories also extends its offerings to include investment management and cell-based assay (CBA) services. Established in 1995, the company is headquartered in Beijing, China.
Latest quote
HK$22.64
+HK$0.16 · +0.71%
Regular session · HKT · Market data may be delayed.
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into three primary divisions: Non-Clinical Studies, Clinical Trial and Related Services, and Research Model Sales. The Non-Clinical Studies segment specializes in comprehensive drug safety assessments, pharmacokinetic and drug metabolism research, and pharmacology and efficacy investigations. Within its Clinical Trial and Related Services segment, the firm delivers clinical contract research organization (CRO) support, co-manages specialized Phase I clinical research facilities, and provides bioanalytical testing. The Research Model Sales division is responsible for the development, breeding, and distribution of diverse animal models for research purposes, encompassing non-human primates and rodents. Furthermore, Joinn Laboratories also extends its offerings to include investment management and cell-based assay (CBA) services. Established in 1995, the company is headquartered in Beijing, China.
Day range
Current HK$22.64
52-week range
Current HK$22.64
Regular session · HKT · Market data may be delayed.
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into three primary divisions: Non-Clinical Studies, Clinical Trial and Related Services, and Research Model Sales. The Non-Clinical Studies segment specializes in comprehensive drug safety assessments, pharmacokinetic and drug metabolism research, and pharmacology and efficacy investigations. Within its Clinical Trial and Related Services segment, the firm delivers clinical contract research organization (CRO) support, co-manages specialized Phase I clinical research facilities, and provides bioanalytical testing. The Research Model Sales division is responsible for the development, breeding, and distribution of diverse animal models for research purposes, encompassing non-human primates and rodents. Furthermore, Joinn Laboratories also extends its offerings to include investment management and cell-based assay (CBA) services. Established in 1995, the company is headquartered in Beijing, China.
Day range
Current HK$22.64
52-week range
Current HK$22.64
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.66B CNY | 2.02B CNY | 2.38B CNY | 2.27B CNY | 1.52B CNY |
| Cost of goods sold | 1.31B CNY | 1.44B CNY | 1.36B CNY | 1.18B CNY | 777.56M CNY |
| Gross profit | 343.31M CNY | 573.77M CNY | 1.01B CNY | 1.09B CNY | 739.12M CNY |
| Research and development | 87.43M CNY | 92.92M CNY | 96.89M CNY | 77.98M CNY | 47.76M CNY |
| Selling, general, and administrative | 120.09M CNY | 118.68M CNY | 100.8M CNY | 96.44M CNY | 112.51M CNY |
| Operating expenses | 5.32M CNY | 469.43M CNY | 505.69M CNY | 369.14M CNY | 287.18M CNY |
| Interest income | 78.19M CNY | 103.23M CNY | 142.5M CNY | 131.23M CNY | 83.72M CNY |
| Interest expense | 1.42M CNY | 325.68K CNY | 3.44M CNY | 3.58M CNY | 3.96M CNY |
| Depreciation and amortization | 144.32M CNY | 130.32M CNY | 129.51M CNY | 120.96M CNY | 96.44M CNY |
| Operating income | 337.99M CNY | 104.35M CNY | 507.1M CNY | 1.23B CNY | 642.89M CNY |
| Net income | 297.84M CNY | 74.08M CNY | 396.99M CNY | 1.07B CNY | 557.46M CNY |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.0328
2025 complete year-78.6% since 2021
2026 partial: HK$0.1379
HK$0.1531
2,021
HK$0.30
2,022
HK$0.44
2,023
HK$0.18
2,024
HK$0.0328
2,025
HK$0.1379
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 22, 2026 | HK$0.1379Annual | Jun 24, 2026 | Aug 4, 2026 |
Dividend | Jun 26, 2025 | HK$0.0328Annual | — | — |
Dividend | Jun 28, 2024 | HK$0.18Annual | — | — |
Dividend | Jun 20, 2023 | HK$0.616Annual | — | — |
Dividend | Jul 28, 2022 | HK$0.588Annual | — | — |
Dividend | Jun 23, 2021 | HK$0.42Annual | — | — |
Ex-dividend Jun 22, 2026
HK$0.1379
Annual
Record Jun 24, 2026 · Payment Aug 4, 2026
Ex-dividend Jun 26, 2025
HK$0.0328
Annual
Ex-dividend Jun 28, 2024
HK$0.18
Annual
Ex-dividend Jun 20, 2023
HK$0.616
Annual
Ex-dividend Jul 28, 2022
HK$0.588
Annual
Ex-dividend Jun 23, 2021
HK$0.42
Annual
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS4.14M0.00%646.2B USD0.05%$88.08-0.37%
Vanguard FTSE Emerging Markets ETFVWO3.91M0.00%162.3B USD0.06%$61.23-0.34%
iShares Core MSCI Emerging Markets ETFIEMG3.06M0.00%163.85B USD0.09%$83.70+0.06%
Vanguard FTSE All-World ex-US ETFVEU633.87K0.00%95.9B USD0.04%$86.06-0.41%
Schwab Emerging Markets Equity ETFSCHE429.42K0.00%13.14B USD0.06%$37.49-0.24%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM231.92K0.00%9.76B USD0.39%$40.94-0.15%
Vanguard Total World Stock ETFVT191.7K0.00%97.9B USD0.06%$160.92-0.50%
Avantis Emerging Markets Equity ETFAVEM182.29K—28.73B USD0.33%$96.20-0.63%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares Core MSCI Emerging Markets ETFIEMGVanguard FTSE All-World ex-US ETFVEUSchwab Emerging Markets Equity ETFSCHEDimensional - Emerging Markets Core Equity 2 ETFDFEMVanguard Total World Stock ETFVTAvantis Emerging Markets Equity ETFAVEMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
